Compare XPER & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPER | ORGO |
|---|---|---|
| Founded | 1990 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.9M | 239.3M |
| IPO Year | 2021 | 2016 |
| Metric | XPER | ORGO |
|---|---|---|
| Price | $5.54 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $11.67 | $8.50 |
| AVG Volume (30 Days) | 357.5K | ★ 609.9K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | ★ N/A | N/A |
| Revenue | $448,105,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $8.11 | $26.27 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $5.07 | $1.47 |
| 52 Week High | $8.75 | $7.08 |
| Indicator | XPER | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 28.06 |
| Support Level | $5.07 | N/A |
| Resistance Level | $5.74 | $2.57 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 6.76 | 0.00 |
Xperi Inc is a media and entertainment technology company. Its technologies are integrated into consumer devices, connected cars, and a variety of media platforms globally, enabling audiences to connect with entertainment content in a more intelligent, immersive, and personal way. As its audiences engage with content on the platform, the company operates a cross-screen advertising solution that enables brands to reach millions of engaged consumers across rapidly expanding digital entertainment ecosystem. It operates in one reportable business segment and group its revenue into four categories: Pay-TV, Consumer Electronics, Connected Car and Media Platform. Geographically it operates in U.S. and Canada, Asia Pacific, Europe, Middle East and Africa, and Other countries.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.